4,707 Eli Lilly and Company $LLY Shares Sold by Vantage Investment Partners LLC

Key Points

• Vantage Investment Partners reduced its Eli Lilly stake by 10.3%, selling 4,707 shares and retaining 40,789 shares valued at approximately $47.2 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, exceeding analyst expectations. Shares were trading near their 52-week high, with a market capitalization of approximately $1.33 trillion.
• Analysts remain broadly bullish, giving the stock a consensus “Moderate Buy” rating and an average price target of $1,398.43, while the company announced a quarterly dividend of $1.73 per share.

Vantage Investment Partners LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.3% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 40,789 shares of the company's stock after selling 4,707 shares during the quarter. Eli Lilly and Company makes up 2.8% of Vantage Investment Partners LLC's holdings, making the stock its 12th largest holding. Vantage Investment Partners LLC's holdings in Eli Lilly and Company were worth $47,196,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Marshall & Sterling Wealth Advisors Inc. grew its stake in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after acquiring an additional 15 shares in the last quarter. Foresight Capital Management Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth $49,000. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $42,000. Caitlin John LLC bought a new stake in Eli Lilly and Company during the second quarter worth approximately $64,000. Finally, IMG Wealth Management Inc. raised its holdings in Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock valued at $72,000 after buying an additional 50 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on LLY shares. Leerink Partners upped their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an "outperform" rating in a research note on Wednesday, October 21st. TD Cowen reiterated a "buy" rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Argus increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a "buy" rating in a research report on Friday. Guggenheim lifted their target price on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a research note on Friday, September 18th. Finally, Truist Financial reaffirmed a "buy" rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,398.43.

Eli Lilly and Company Trading Up 3.1%

Shares of LLY opened at $1,415.64 on Friday. Eli Lilly and Company has a 52-week low of $834.19 and a 52-week high of $1,449.68. The stock has a market cap of $1.33 trillion, a PE ratio of 45.95, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm's fifty day moving average is $1,197.72 and its two-hundred day moving average is $1,092.57.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 93.68% and a net margin of 31.90%. The business's revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $7.02 EPS. Research analysts forecast that Eli Lilly and Company will post 35.50 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Insider Activity

In related news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.